Is Tofacitinib a hormonal drug?

Tofacitinib is not a hormonal drug. It is a small molecule oral immunomodulator that mainly inhibits JAK1 and JAK3 in the Januskinase (JAK) family, thereby interfering with intracellular signaling and regulating immune responses. The mechanism of action of tofacitinib is completely different from that of hormone drugs. Hormone drugs mainly work through the regulation of gene expression mediated by hormone receptors, while tofacitinib directly acts on cell signaling pathways.

Tofacitinib is mainly used to treat immune-mediated diseases such as rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. It inhibits the activity of JAK enzyme, blocks the signal transmission of various inflammatory factors, reduces the inflammatory response, and thereby relieves the patient's symptoms. Compared with traditional hormone therapy, tofacitinib is more targeted in immune regulation and does not cause common side effects of hormone drugs such as weight gain, edema, osteoporosis and other side effects.

Hormone drugs such as glucocorticoids play an important role in immunosuppression, but long-term use of hormonal drugs is often associated with many side effects. The emergence of tofacitinib brings new options for the treatment of immune system diseases, especially for patients who need long-term management of immune system activity. Although both can inhibit inflammation, tofacitinib's mechanism of action and side effect spectrum are significantly different and more precise and controllable.

To sum up, tofacitinib is not a hormonal drug, but a small molecule inhibitor targeting the JAK signaling pathway. It exerts therapeutic effects by regulating the signal transmission of the immune system and is an important innovative drug in the treatment of modern immune diseases. Patients should follow medical advice when using it and avoid confusion with hormonal drugs to ensure the safety and effectiveness of treatment.

Reference materials:https://www.xeljanz.com/